All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia

July 14th 2025

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Molecular Insights Guide First-Line and Post-Transplant Strategies in AML

July 14th 2025

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Relacorilant Plus Nab-Paclitaxel Provides PFS Benefit in Platinum-Resistant Ovarian Cancer

July 14th 2025

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from ROSELLA trial and where the future is headed for studying relacorilant in PROC.

Mayo Clinic Researchers Link CAR-T Cell Aging to Cancer Relapse

July 14th 2025

Mayo Clinic researchers have discovered a key reason some patients with cancer relapse after receiving CAR T-cell therapy.

FDA Receives NDA for Relacorilant in Platinum-Resistant Ovarian Cancer

July 14th 2025

The FDA received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 14th 2025

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

Regorafenib Plus Trifluridine/Tipiracil Shows Early Efficacy in Refractory Metastatic Colorectal Cancer

July 14th 2025

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Pasritamig Displays Safety, Durable Disease Control in Heavily Pretreated mCRPC

July 14th 2025

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

Adjuvant Dalpiciclib Plus Endocrine Therapy Improves iDFS in HR+/HER2– Early Breast Cancer

July 14th 2025

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’

July 13th 2025

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Cross-Disciplinary Expert Alliances Drive Progress in Malignant PEComa Diagnosis and Management

July 12th 2025

Richard F. Riedel, MD, discusses the rarity of PEComa, challenges with managing this disease, and the role of sarcoma specialists in staging and treatment.

Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress

July 11th 2025

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Most Patients With Advanced Melanoma Who Received Pre-Surgical Immunotherapy Remain Alive and Disease Free Four Years Later

July 11th 2025

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Lisaftoclax Wins Chinese Approval in Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

July 11th 2025

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 11th 2025

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

A Closer Look at Issues With the Expanding Role of Precision Medicine in Cancer Management

July 11th 2025

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL

July 11th 2025

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.